Arcus Biosciences Inc (NYSE:RCUS)
$ 15.07 0.14 (0.94%) Market Cap: 1.37 Bil Enterprise Value: 373.93 Mil PE Ratio: 0 PB Ratio: 1.94 GF Score: 73/100

Q3 2023 Arcus Biosciences Inc Earnings Call Transcript

Nov 07, 2023 / 10:00PM GMT
Release Date Price: $16.45 (+5.65%)
Operator

Thank you, and welcome to the call. Following prepared remarks from the company, we will open the call for questions. (Operator Instructions) This call is being recorded and will be available on the Investors section of the Arcus website.

I will now turn the meeting over to Pia Eaves, Head of Investor Relations and Strategy.

Pia Eaves

Hello, everyone, and thank you for joining us on today's conference call to discuss Arcus' third quarter 2023 financial results and pipeline updates, including today's presentation of data from our EDGE-Gastric trial at the ASCO monthly Plenary. Today, you will hear from Terry Rosen, Chief Executive Officer; Dimitry Nuyten, Chief Medical Officer; Jennifer Jarrett, Chief Operating Officer; and Bob Goeltz, Chief Financial Officer. For Q&A, we will also be joined by Juan Jaen, President and Head of Research.

I'd like to remind you that on this call, management will be making forward-looking statements, including statements about our cash runway, our investigational products, our expected clinical development

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot